Search

Your search keyword '"Scrivo, R."' showing total 263 results
Start Over Author "Scrivo, R."
263 results on '"Scrivo, R."'

1. Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

Author

Gioia, C., primary, Picchianti Diamanti, A., additional, Perricone, R., additional, Chimenti, M.S., additional, Afeltra, A., additional, Navarini, L., additional, Migliore, A., additional, Massafra, U., additional, Bruzzese, V., additional, Scolieri, P., additional, Meschini, C., additional, Paroli, M., additional, Caccavale, R., additional, Scapato, P., additional, Scrivo, R., additional, Conti, F., additional, Laganà, B., additional, and Di Franco, M., additional

Published
2023
Full Text
View/download PDF

4. AB0429 EIGHT-MONTH FOLLOW-UP OF THE NON-MEDICAL SWITCH FROM ETANERCEPT BIO-ORIGINATOR TO GP-2015 OR SB4 ETANERCEPT BIOSIMILARS IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES: A MONOCENTRIC OBSERVATIONAL STUDY

Author

Castellani, C., primary, Di Sanzo, L., additional, Bevignani, G., additional, Molteni, E., additional, Sciarra, G., additional, Di Franco, M., additional, Alessandri, C., additional, Riccieri, V., additional, Priori, R., additional, Ceccarelli, F., additional, Spinelli, F. R., additional, Scrivo, R., additional, and Conti, F., additional

Published
2023
Full Text
View/download PDF

6. AB0175 EVALUATION OF THE STATE OF ACTIVATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN PATIENTS WITH POLYMYALGIA RHEUMATICA

Author

Castellani, C., primary, Colafrancesco, S., additional, Barbati, C., additional, Truglia, S., additional, Buoncuore, G., additional, Priori, R., additional, Sili Scavalli, A., additional, Molteni, E., additional, Sciarra, G., additional, Di Sanzo, L., additional, Bevignani, G., additional, Conti, F., additional, and Scrivo, R., additional

Published
2023
Full Text
View/download PDF

7. Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: A 12-month prospective observational study

Author

D Angelo, S, Malavolta, N, Scambi, C, Salvarani, C, Caso, F, Tirri, E, Ramonda, R, Quarta, L, Erre, G, Riva, M, Buono, R, Furini, F, Grembiale, R, Lomater, C, Cantini, F, Maio, T, Chimenti, M, Scrivo, R, Salaffi, F, Caporali, R, Volpe, P, Gualberti, G, Marando, F, Marchesoni, A, D Angelo S., Malavolta N., Scambi C., Salvarani C., Caso F., Tirri E., Ramonda R., Quarta L., Erre G. L., Riva M., Buono R., Furini F., Grembiale R. D., Lomater C., Cantini F., Maio T., Chimenti M. S., Scrivo R., Salaffi F., Caporali R. F., Volpe P., Gualberti G., Marando F., Marchesoni A., D Angelo, S, Malavolta, N, Scambi, C, Salvarani, C, Caso, F, Tirri, E, Ramonda, R, Quarta, L, Erre, G, Riva, M, Buono, R, Furini, F, Grembiale, R, Lomater, C, Cantini, F, Maio, T, Chimenti, M, Scrivo, R, Salaffi, F, Caporali, R, Volpe, P, Gualberti, G, Marando, F, Marchesoni, A, D Angelo S., Malavolta N., Scambi C., Salvarani C., Caso F., Tirri E., Ramonda R., Quarta L., Erre G. L., Riva M., Buono R., Furini F., Grembiale R. D., Lomater C., Cantini F., Maio T., Chimenti M. S., Scrivo R., Salaffi F., Caporali R. F., Volpe P., Gualberti G., Marando F., and Marchesoni A.

Abstract

Objective To evaluate the health-related quality of life (HRQoL), disease activity, treatment adherence, and work ability in the real-world setting in patients with axial spondyloarthritis (axSpA). Methods QUASAR was a prospective 12-month, observational study involving 23 rheumatology centres across Italy, including adult patients with axSpA according to the Assessment of SpondyloArthritis International Society (ASAS) criteria. Patients were followed at baseline, 3, 6, and 12 months for disease activity and health-related QoL (HRQoL), treatment adherence and work ability. Regression analysis was used to assess the association between treatment and outcome variables. Results 413 (80.7%) out of axSpA 512 patients were diagnosed with ankylosing spondylitis (AS) and 99 (19.3%) with non-radiographic axSpA (nr-AxSpA). Nr-AxSpA and AS patients had similar baseline disease activity and HRQoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) were the most frequent medication (n=426, 83.2%). Over the 1-year follow-up, disease activity measures (joint pain and swelling, CRP, global assessment, BASDAI, ASDAS), HRQoL and work ability significantly improved, while few differences emerged between nr-AxSpA and AS patients. Treatment satisfaction and adherence questionnaires improved over the 12 months. Patients treated with bDMARDs showed improved outcomes for disease activity measures and HRQoL variables, greater benefit observed in patients with AS. Conclusion We found clinical and HRQoL improvement over 1 year in a large, real-world population of nr-AxSpA and AS patients treated with bDMARDs or conventional synthetic DMARDs.

Published
2021

9. AB0380 ANTI-TNFα: ORIGINATORS vs BIOSIMILARS, COMPARISON IN CLINICAL RESPONSE ASSESSMENT IN A MULTICENTER COHORT OF PATIENTS WITH INFLAMMATORY ARTHROPATHIES

Author

Gioia, C., primary, Picchianti-Diamanti, A., additional, Perricone, R., additional, Chimenti, M. S., additional, Afeltra, A., additional, Navarini, L., additional, Migliore, A., additional, Massafra, U., additional, Bruzzese, V., additional, Scolieri, P., additional, Meschini, C., additional, Scapato, P., additional, Paroli, M., additional, Scrivo, R., additional, Conti, F., additional, Laganà, B., additional, and Di Franco, M., additional

Published
2022
Full Text
View/download PDF

11. POS1076 OBESITY IS ASSOCIATED WITH LESS LIKELIHOOD OF REMISSION/ LOW DISEASE IN PSORIATIC ARTHRITIS, A CROSS-SECTIONAL STUDY OF 414 PATIENTS

Author

Leung, Y. Y., primary, Eder, L., additional, Orbai, A. M., additional, Coates, L., additional, De Wit, M., additional, Smolen, J. S., additional, Kiltz, U., additional, Palominos, P., additional, Cañete, J. D. D., additional, Scrivo, R., additional, Balanescu, A., additional, Dernis, E., additional, Meisalu, S., additional, Soubrier, M., additional, Kalyoncu, U., additional, and Gossec, L., additional

Published
2022
Full Text
View/download PDF

13. POS0004 WHAT DOES WORSENING IN DAPSA DISEASE ACTIVITY CATEGORIES MEAN FOR PATIENTS WITH PSORIATIC ARTHRITIS? AN ANALYSIS OF 222 PATIENTS

Author

Sousa, M., primary, Smolen, J. S., additional, Gorlier, C., additional, de Wit, M., additional, Coates, L., additional, Kalyoncu, U., additional, Ruyssen-Witrand, A., additional, Leung, K., additional, Scrivo, R., additional, Cañete, J. d. D., additional, Palominos, P., additional, Meisalu, S., additional, Balanescu, A., additional, Kiltz, U., additional, Aydin, S., additional, Gaydukova, I., additional, Dernis, E., additional, Fautrel, B., additional, Orbai, A. M., additional, Lubrano, E., additional, and Gossec, L., additional

Published
2022
Full Text
View/download PDF

14. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases

Author

Guerrini, G, Franzetti, F, Giacomelli, R, Meroni, L, Riva, A, Scire, C, Scrivo, R, Tavio, M, Agostinone, A, Airo, P, Atzeni, F, Bartalesi, F, Bazzichi, L, Berardicurti, O, Cassola, G, Castagna, A, Castelli, F, Cattelan, A, Citriniti, G, Cristini, F, De Rosa, F, Fracassi, E, Galloway, J, La Paglia, G, Moioli, M, Ripamonti, D, Saracino, A, Tani, C, Tascini, C, Tieghi, T, Tinelli, M, Zabotti, A, Sarzi-Puttini, P, Galli, M, Guerrini G., Franzetti F., Giacomelli R., Meroni L., Riva A., Scire C. A., Scrivo R., Tavio M., Agostinone A., Airo P., Atzeni F., Bartalesi F., Bazzichi L., Berardicurti O., Cassola G., Castagna A., Castelli F., Cattelan A., Citriniti G., Cristini F., De Rosa F., Fracassi E., Galloway J., La Paglia G. M. C., Moioli M. C., Ripamonti D., Saracino A., Tani C., Tascini C., Tieghi T., Tinelli M., Zabotti A., Sarzi-Puttini P., Galli M., Guerrini, G, Franzetti, F, Giacomelli, R, Meroni, L, Riva, A, Scire, C, Scrivo, R, Tavio, M, Agostinone, A, Airo, P, Atzeni, F, Bartalesi, F, Bazzichi, L, Berardicurti, O, Cassola, G, Castagna, A, Castelli, F, Cattelan, A, Citriniti, G, Cristini, F, De Rosa, F, Fracassi, E, Galloway, J, La Paglia, G, Moioli, M, Ripamonti, D, Saracino, A, Tani, C, Tascini, C, Tieghi, T, Tinelli, M, Zabotti, A, Sarzi-Puttini, P, Galli, M, Guerrini G., Franzetti F., Giacomelli R., Meroni L., Riva A., Scire C. A., Scrivo R., Tavio M., Agostinone A., Airo P., Atzeni F., Bartalesi F., Bazzichi L., Berardicurti O., Cassola G., Castagna A., Castelli F., Cattelan A., Citriniti G., Cristini F., De Rosa F., Fracassi E., Galloway J., La Paglia G. M. C., Moioli M. C., Ripamonti D., Saracino A., Tani C., Tascini C., Tieghi T., Tinelli M., Zabotti A., Sarzi-Puttini P., and Galli M.

Abstract

OBJECTIVES: To provide evidence-based recommendations for vaccination against influenza virus and S. pneumoniae in patients with autoimmune rheumatic diseases (ARDs). METHODS: A Consensus Committee including physicians with expertise in rheumatic and infectious diseases was established by two Italian scientific societies, Società Italiana di Reumatologia (SIR) and Società Italiana di Malattie Infettive e Tropicali (SIMIT). The experts were invited to develop evidence-based recommendations concerning vaccinations in ARDs patients, based on their clinical status before and after undergoing immunosuppressive treatments. Key clinical questions were formulated for the systematic literature reviews, based on the clinical pathway. A search was made in Medline (via PubMed) according to the original MeSH strategy from October 2009 and a keyword strategy from January 2016 up to December 2017, updating existing EULAR recommendations. Specific recommendations were separately voted and scored from 0 (no agreement with) to 100 (maximal agreement) and supporting evidence graded. The mean and standard deviation of the scores were calculated to determine the level of agreement among the experts' panel for each recommendation. Total cumulative agreement ≥70 defined consensus for each statement. RESULTS: Nine recommendations, based on 6 key clinical questions addressed by the expert committee, were proposed. The aim of this work is to integrate the 2011 EULAR recommendations on vaccination against influenza and S. pneumoniae in ARDs patients. An implementation plan was proposed to improve the vaccination status of these patients and their safety during immunosuppressive treatments. CONCLUSIONS: Influenza and pneumococcus vaccinations are effective and safe in patients with ARDs. More efforts should be made to translate the accumulated evidence into practice.

Published
2020

15. Les patients atteints de rhumatisme psoriasique sont-ils traités de manière optimale autour du monde ? Disparités entre pays dans le rhumatisme psoriasique : une analyse de 410 patients provenant de 13 pays

Author

Lucasson, F., primary, Kiltz, U., additional, Kalyoncu, U., additional, Leung, Y.Y., additional, Palominos, P., additional, Cañete, J.D., additional, Scrivo, R., additional, Balanescu, A., additional, Dernis, E., additional, Meisalu, S., additional, Ruyssen-Witrand, A., additional, Soubrier, M., additional, Aydin, S.Z., additional, Eder, L., additional, Gaydukova, I., additional, Lubrano, E., additional, Richette, P., additional, Husni, E., additional, Coates, L., additional, De Wit, M., additional, Smolen, J.S., additional, Orbai, A.M., additional, and Gossec, L., additional

Published
2021
Full Text
View/download PDF

17. Erratum: Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- And consensus-based statements by a panel of Italian experts (Arthritis Res Ther (2019) 21:275 DOI: 10.1186/s13075-019-2021-9)

Author

Colafrancesco, S., Manara, M., Bortoluzzi, A., Serban, T., Bianchi, G., Cantarini, L., Ciccia, F., Dagna, L., Govoni, M., Montecucco, C., Priori, R., Ravelli, A., Sfriso, P., Sinigaglia, L., Alivernini, S., Baldissera, E., Bartoloni, E., Berti, A., Bugatti, S., Camellino, D., Cammelli, D., Caporali, R., Caso, F., Cavallaro, E., Cavalli, G., Colaci, M., Costa, L., Di Scala, G., Emmi, G., Frassi, M., Gerli, R., Giacomelli, R., Gremese, E., Iannone, F., Lapadula, G., Leveghi, L., Lopalco, G., Manna, R., Marotto, D., Mathieu, A., Neri, R., Patisso, I., Piga, M., Punzi, L., Romano, M., Ruscitti, P., Salvarani, C., Scarpa, R., Scrivo, R., Talarico, R., Verrecchia, E., Viapiana, O., Vitale, A., Vitiello, G., Colafrancesco, S., Manara, M., Bortoluzzi, A., Serban, T., Bianchi, G., Cantarini, L., Ciccia, F., Dagna, L., Govoni, M., Montecucco, C., Priori, R., Ravelli, A., Sfriso, P., Sinigaglia, L., Alivernini, S., Baldissera, E., Bartoloni, E., Berti, A., Bugatti, S., Camellino, D., Cammelli, D., Caporali, R., Caso, F., Cavallaro, E., Cavalli, G., Colaci, M., Costa, L., Di Scala, G., Emmi, G., Frassi, M., Gerli, R., Giacomelli, R., Gremese, E., Iannone, F., Lapadula, G., Leveghi, L., Lopalco, G., Manna, R., Marotto, D., Mathieu, A., Neri, R., Patisso, I., Piga, M., Punzi, L., Romano, M., Ruscitti, P., Salvarani, C., Scarpa, R., Scrivo, R., Talarico, R., Verrecchia, E., Viapiana, O., Vitale, A., and Vitiello, G.

Abstract

Following publication of the original article [1], it was brought to our attention that the AOSD Consensus Group was incorrectly tagged and therefore not searchable. The publishers apologize for this error.

Published
2020

19. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis

Author

Sebastiani, M, Milazzo, L, Atzeni, F, Vacchi, C, Manfredi, A, Quartuccio, L, Scire, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, D'Angelo, S, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M., Milazzo L., Atzeni F., Vacchi C., Manfredi A., Quartuccio L., Scire C., Gaeta G. B., Lapadula G., Armignacco O., Tavio M., D'Angelo S., Meroni P., Bazzichi L., Grassi W., Mathieu A., Mastroianni C., Sagnelli E., Santantonio T., Foppa C. U., Puoti M., Sarmati L., Airo P., Epis O. M., Scrivo R., Gargiulo M., Riva A., Ciancio G., Zehender G., Taliani G., Meroni L., Sollima S., Sarzi-Puttini P., Galli M., Sebastiani, M, Milazzo, L, Atzeni, F, Vacchi, C, Manfredi, A, Quartuccio, L, Scire, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, D'Angelo, S, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M., Milazzo L., Atzeni F., Vacchi C., Manfredi A., Quartuccio L., Scire C., Gaeta G. B., Lapadula G., Armignacco O., Tavio M., D'Angelo S., Meroni P., Bazzichi L., Grassi W., Mathieu A., Mastroianni C., Sagnelli E., Santantonio T., Foppa C. U., Puoti M., Sarmati L., Airo P., Epis O. M., Scrivo R., Gargiulo M., Riva A., Ciancio G., Zehender G., Taliani G., Meroni L., Sollima S., Sarzi-Puttini P., and Galli M.

Abstract

Objectives: The recent introduction of direct-acting antiviral agents (DAAs) which can eliminate Hepatitis C virus (HCV) had revolutionized the treatment of HCV infections also in a complex clinical setting such as the patients with rheumatoid arthritis (RA). HCV elimination is also opportune due to the availability of more efficient immunosuppressive drugs, whose effect on the course of HCV infection is largely unknown. Methods: Consensus process was endorsed by the Italian Society of Rheumatology (SIR) and the Italian Society of Infectious and Tropical Diseases (SIMIT) to review the available evidence and produce practical, hospital-wide recommendations. The consensus panel consisted of 18 infectious diseases consultants, 20 rheumatologists and one clinical epidemiologist, who used the criteria of the Oxford Centre for Evidence-based Medicine to assess the quality of the evidence and the strength of their recommendations. Results: A core-set of statements about management of patients with RA and infection by HCV have been developed to help clinicians in their clinical practice. Conclusions: A screening for HCV should be performed in all RA patients and it is mandatory before starting an immunosuppressive therapy. Finally, a DAA treatment should be considered in all HCV-infected patients.Significance and Innovations HCV antibodies should be investigated at the time of diagnosis of RA and, in any case, before starting immunosuppressive therapy with disease-modifying antirheumatic drugs (DMARDs). HCV eradication with DAA should be attempted as soon as possible, depending on patient conditions allowing a continuous oral treatment lasting 8–12 weeks Conventional and biological DMARDs are allowed in patients with HCV infection, but they should be used cautiously in presence of advanced liver disease.

Published
2019

20. Effectiveness and safety of baricitinib in rheumatoid arthritis. a monocentric, longitudinal, real-life experience

Author

Spinelli, F. R., Ceccarelli, F., Garufi, C., Duca, I., Mancuso, S., Cipriano, E., Dell’unto, E., Alessandri, C., Di Franco, M., Perricone, C., Priori, R., Valeria RICCIERI, Scrivo, R., Sili Scavalli, A., Truglia, S., Valesini, G., and Conti, F.

Subjects
rheumatoid arthritis, safety, Sulfonamides, therapy, Immunology, effectiveness, Middle Aged, Arthritis, Rheumatoid, remission, Rheumatology, Purines, Antirheumatic Agents, Immunology and Allergy, Azetidines, Humans, Pyrazoles, baricitinib, safety, remission, pain
Abstract

Baricitinib is a Janus-kinase (JAK) 1/2 inhibitor, approved for the treatment of moderate-to-severe rheumatoid arthritis (RA) patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). We report the first real-life experience with baricitinib in a monocentric cohort of unselected RA patients.We enrolled consecutive RA patients starting baricitinib. At baseline and after 4, 12, 24 and 48 weeks we assessed the disease activity by composite indices (SDAI, CDAI and DAS28CRP) and ultrasonography, and we recorded any adverse events. The primary endpoint was the percentage of patients achieving SDAI remission at week 4.We enrolled 59 patients [(F:M = 50:9, median age 58.1 years (IQR 12.8), median disease duration 144 (IQR 150) months] treated with baricitinib in combination with a csDMARD (52.5%) or monotherapy (47.5%) for a median follow-up of 24 weeks (IQR 36). The 12-month drug retention rate was 74%. At weeks 4, 12, 24 and 48 we observed a significant reduction of DAS28, CDAI and SDAI, global health and pain (p0.001 for all). After 4 weeks of treatment, 12% of patients achieved SDAI remission. Concomitant csDMARDs, previous biological DMARDs, gender, seropositivity and BMI did not affect the efficacy of baricitinib. Baricitinib allowed a significant reduction in prednisone dose after 12 and 24 weeks and a rapid and sustained ultrasound improvement. No serious adverse events, serious infections or cardiovascular events were recorded.Our study confirms the efficacy and safety profile and rapid onset of the effect of baricitinib in RA patients in a real-life setting.

Published
2021

22. OP0298 ARE PATIENTS WITH PSORIATIC ARTHRITIS BEING TREATED OPTIMALLY ACROSS THE WORLD? DISPARITIES IN HEALTH CARE FOR PATIENTS WITH PSORIATIC ARTHRITIS ACROSS COUNTRIES WITH DIFFERENT GDP’S, AN ANALYSIS OF 429 PATIENTS FROM 13 COUNTRIES

Author

Lucasson, F., primary, Kiltz, U., additional, Cañete, J. D. D., additional, Orbai, A. M., additional, Leung, Y. Y., additional, Palominos, P., additional, Balanescu, A., additional, Meisalu, S., additional, Ruyssen-Witrand, A., additional, Soubrier, M., additional, Eder, L., additional, Gaydukova, I., additional, Kalyoncu, U., additional, Richette, P., additional, De Wit, M., additional, Lubrano, E., additional, Smolen, J. S., additional, Coates, L. C., additional, Scrivo, R., additional, Dernis, E., additional, Aydin, S., additional, Husni, M. E., additional, and Gossec, L., additional

Published
2021
Full Text
View/download PDF

27. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases

Author

Guerrini, G., Franzetti, F., Giacomelli, R., Meroni, L., Riva, A., Scirè, C. A., Scrivo, R., Tavio, M., Agostinone, A., Airò, P., Atzeni, F., Bartalesi, F., Bazzichi, L., Berardicurti, O., Cassola, G., antonella castagna, Castelli, F., Cattelan, A., Citriniti, G., Cristini, F., Rosa, F., Fracassi, E., Galloway, J., La Paglia, G. M. C., Moioli, M. C., Ripamonti, D., Saracino, A., Tani, C., Tascini, C., Tieghi, T., Tinelli, M., Zabotti, A., Sarzi-Puttini, P., Galli, M., Guerrini, G, Franzetti, F, Giacomelli, R, Meroni, L, Riva, A, Scire, C, Scrivo, R, Tavio, M, Agostinone, A, Airo, P, Atzeni, F, Bartalesi, F, Bazzichi, L, Berardicurti, O, Cassola, G, Castagna, A, Castelli, F, Cattelan, A, Citriniti, G, Cristini, F, De Rosa, F, Fracassi, E, Galloway, J, La Paglia, G, Moioli, M, Ripamonti, D, Saracino, A, Tani, C, Tascini, C, Tieghi, T, Tinelli, M, Zabotti, A, Sarzi-Puttini, P, Galli, M, Guerrini, Giulio, Franzetti, Fabio, Giacomelli, Roberto, Meroni, Luca, Riva, Agostino, Scirè, Carlo Alberto, Scrivo, Rossana, Tavio, Marcello, Agostinone, Adriana, Airò, Paolo, Atzeni, Fabiola, Bartalesi, Filippo, Bazzichi, Laura, Berardicurti, Onorina, Cassola, Giovanni, Castagna, Antonella, Castelli, Francesco, Cattelan, Annamaria, Citriniti, Giorgia, Cristini, Francesco, De Rosa, Francesco, Fracassi, Elena, Galloway, Jame, La Paglia, Giuliana Maria Concetta, Moioli, Maria Cristina, Ripamonti, Diego, Saracino, Annalisa, Tani, Chiara, Tascini, Carlo, Tieghi, Tiziana, Tinelli, Marco, Zabotti, Alen, Sarzi-Puttini, Piercarlo, and Galli, Massimo

Subjects
Adult, Male, pneumococcal vaccine, Consensus, infuenza vaccine, Immunology, vaccination, autoimmune disease, NO, recommendations, influenza vaccination, pneumococcal vaccination, autoimmune rheumatic diseases, Autoimmune Diseases, Pneumococcal Vaccines, Rheumatology, Rheumatic Diseases, Influenza, Human, Pneumonia, Staphylococcal, Immunology and Allergy, Humans, disease-modifying anti-rheumatic drugs, Evidence-Based Medicine, Vaccination, Pneumonia, Influenza, disease-modifying anti-rheumatic drugs, autoimmune rheumatic diseases, infuenza vaccine, pneumococcal vaccine, Italy, Influenza Vaccines, Staphylococcal, Female, Immunosuppressive Agents, Human
Abstract

OBJECTIVES: To provide evidence-based recommendations for vaccination against influenza virus and S. pneumoniae in patients with autoimmune rheumatic diseases (ARDs). METHODS: A Consensus Committee including physicians with expertise in rheumatic and infectious diseases was established by two Italian scientific societies, Società Italiana di Reumatologia (SIR) and Società Italiana di Malattie Infettive e Tropicali (SIMIT). The experts were invited to develop evidence-based recommendations concerning vaccinations in ARDs patients, based on their clinical status before and after undergoing immunosuppressive treatments. Key clinical questions were formulated for the systematic literature reviews, based on the clinical pathway. A search was made in Medline (via PubMed) according to the original MeSH strategy from October 2009 and a keyword strategy from January 2016 up to December 2017, updating existing EULAR recommendations. Specific recommendations were separately voted and scored from 0 (no agreement with) to 100 (maximal agreement) and supporting evidence graded. The mean and standard deviation of the scores were calculated to determine the level of agreement among the experts' panel for each recommendation. Total cumulative agreement ≥70 defined consensus for each statement. RESULTS: Nine recommendations, based on 6 key clinical questions addressed by the expert committee, were proposed. The aim of this work is to integrate the 2011 EULAR recommendations on vaccination against influenza and S. pneumoniae in ARDs patients. An implementation plan was proposed to improve the vaccination status of these patients and their safety during immunosuppressive treatments. CONCLUSIONS: Influenza and pneumococcus vaccinations are effective and safe in patients with ARDs. More efforts should be made to translate the accumulated evidence into practice.

Published
2019

28. Correction

Author

Sebastiani, M, Milazzo, L, Atzeni, F, Vacchi, C, Manfredi, A, Quartuccio, L, Scire, C, Gaeta, GB, Lapadula, G, Armignacco, O, Tavio, M, D'Angelo, S, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, OM, Scrivo, R, Gargiulo, M, Riva, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani, M, Milazzo, L, Atzeni, F, Vacchi, C, Manfredi, A, Quartuccio, L, Scire, C, Gaeta, Gb, Lapadula, G, Armignacco, O, Tavio, M, D'Angelo, S, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, Om, Scrivo, R, Gargiulo, M, Riva, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, and Galli, M

Published
2019

29. FRI0270 ONE-YEAR EFFECTIVENESS, RETENTION RATE AND SAFETY OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: A REAL-LIFE MULTICENTRE STUDY

Author

Chimenti, M. S., primary, Fonti, G. L., additional, Conigliaro, P., additional, Sunzini, F., additional, Scrivo, R., additional, Navarini, L., additional, Triggianese, P., additional, Peluso, G., additional, Scolieri, P., additional, Caccavale, R., additional, Picchianti-Diamanti, A., additional, De Martino, E., additional, Salemi, S., additional, Birra, D., additional, Altobelli, A., additional, Paroli, M., additional, Bruzzese, V., additional, Laganà, B., additional, Gremese, E., additional, Conti, F., additional, Afeltra, A., additional, and Perricone, R., additional

Published
2020
Full Text
View/download PDF

31. SAT0412 ACCURACY OF AN INSTRUMENT FOR SCREENING PSORIATIC ARTHRITIS AMONG PSORIATIC PATIENTS: RESULTS FROM THE MULTICENTRE ITALIAN STUDY HERACLES (SCREENING STRATEGIES FOR RHEUMATOLOGICAL REFERRAL OF PSORIATIC SUBJECTS AIMED TO DISCLOSE PSORIATIC ARTHRITIS)

Author

De Marco, G., primary, Manara, M., additional, Gisondi, P., additional, Idolazzi, L., additional, Ramonda, R., additional, Piaserico, S., additional, Cauli, A., additional, Cimmino, M. A., additional, Tomatis, V., additional, Salvarani, C., additional, Scrivo, R., additional, Zanetti, A., additional, Carrara, G., additional, Scirè, C. A., additional, Cattaneo, A., additional, and Marchesoni, A., additional

Published
2020
Full Text
View/download PDF

33. SAT0555 MUSCULOSKELETAL ULTRASOUND IN MONITORING RESPONSE TO JAKi IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM A LONGITUDINAL STUDY

Author

Cipriano, E., primary, Ceccarelli, F., additional, Spinelli, F. R., additional, Garufi, C., additional, Duca, I., additional, Mancuso, S., additional, Alessandri, C., additional, DI Franco, M., additional, Priori, R., additional, Riccieri, V., additional, Scrivo, R., additional, Perricone, C., additional, Valesini, G., additional, and Conti, F., additional

Published
2020
Full Text
View/download PDF

34. Italian consensus guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis [Prise en charge de l'infection par le virus de l'hépatite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne]

Author

Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scire', C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M., Atzeni F., Milazzo L., Quartuccio L., Scire' C., Gaeta G. B., Lapadula G., Armignacco O., Tavio M., Olivieri I., Meroni P., Bazzichi L., Grassi W., Mathieu A., Mastroianni C., Sagnelli E., Santantonio T., Uberti Foppa C., Puoti M., Sarmati L., Airo P., Epis O. M., Scrivo R., Gargiulo M., Riva A., Manfredi A., Ciancio G., Zehender G., Taliani G., Meroni L., Sollima S., Sarzi-Puttini P., Galli M., Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scire', C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M., Atzeni F., Milazzo L., Quartuccio L., Scire' C., Gaeta G. B., Lapadula G., Armignacco O., Tavio M., Olivieri I., Meroni P., Bazzichi L., Grassi W., Mathieu A., Mastroianni C., Sagnelli E., Santantonio T., Uberti Foppa C., Puoti M., Sarmati L., Airo P., Epis O. M., Scrivo R., Gargiulo M., Riva A., Manfredi A., Ciancio G., Zehender G., Taliani G., Meroni L., Sollima S., Sarzi-Puttini P., and Galli M.

Published
2018

36. An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab

Author

Scrivo, R., Giardino, A. M., Salvarani, C., Foti, R., Afeltra, A., Viapiana, O., Giacomelli, R., Salaffi, F., Galeazzi, M., Ramonda, R., Ciccia, F., Valesini, G., Florenzo Iannone, Scrivo, Rossana, Giardino, Angela M, Salvarani, Carlo, Foti, Rosario, Afeltra, Antonella, Viapiana, Ombretta, Giacomelli, Roberto, Salaffi, Fausto, Galeazzi, Mauro, Ramonda, Roberta, Ciccia, Francesco, Valesini, Guido, and Iannone, Florenzo

Subjects
psoriatic arthritis, Arthritis, Arthritis, Psoriatic, Antibodies, Monoclonal, Psoriatic, urologic and male genital diseases, Prognosis, Antibodies, Treatment Outcome, humans, prognosis, prospective studies, treatment outcome, antibodies, monoclonal, antirheumatic agents, Antirheumatic Agents, Monoclonal, Humans, Prospective Studies
Abstract

Recently, research has been focused on the identification of predictors of response to treatment in patients with active psoriatic arthritis (PsA). The objective of this study was to develop a model to predict the clinical response at 6 months in patients with PsA starting the anti-tumour necrosis factor-α golimumab.This prospective observational study explored a range of factors, including demographic data and baseline characteristics of the disease, measures of disease activity and functional disability, and potential laboratory biomarkers in the prediction of response, defined as the achievement of modified-minimal disease activity (mMDA), to golimumab in PsA patients.We studied 151 PsA patients starting golimumab because of their active disease. After 6 months, the rate of drug persistence on golimumab was 80%, and mMDA was achieved in 44.3% of patients. Using univariate and multivariate logistic regression models, lower disease activity in PsA score (DAPSA) at baseline (odds ratio [OR] 0.92; 95% confidence interval [CI] 0.89-0.96, p0.001) was independent predictor of mMDA at 6 months. High sensitivity C-reactive protein value (OR 1.06; 95% CI 1.00-1.13, p=0.026) at baseline also was a predictive factor of mMDA achievement at 6 months in the laboratory-enhanced prediction model. Golimumab was safe and well tolerated.The identification of factors predictive of response to treatment may help in better understanding the response to golimumab and in identifying PsA patients that are most likely to achieve mMDA following therapy with golimumab.

Published
2020

37. Erratum. management of adult-onset still's disease with interleukin-1 inhibitors. evidence- and consensus-based statements by a panel of Italian experts

Author

Colafrancesco, S., Manara, M., Bortoluzzi, A., Serban, T., Bianchi, G., Cantarini, L., Ciccia, F., Dagna, L., Govoni, M., Montecucco, C., Priori, R., Ravelli, A., Sfriso, P., Sinigaglia, L., Alivernini, S., Baldissera, E., Bartoloni, E., Berti, A., Bugatti, S., Camellino, D., Cammelli, D., Caporali, R., Caso, F., Cavallaro, E., Cavalli, G., Colaci, M., Costa, L., Di Scala, G., Emmi, G., Frassi, M., Gerli, R., Giacomelli, R., Gremese, E., Iannone, F., Lapadula, G., Leveghi, L., Lopalco, G., Manna, R., Marotto, D., Mathieu, A., Neri, R., Patisso, I., Piga, M., Punzi, L., Romano, M., Ruscitti, P., Salvarani, C., Scarpa, R., Scrivo, R., Talarico, R., Verrecchia, E., Viapiana, O., Vitale, A., and Vitiello, G.

Subjects
030203 arthritis & rheumatology, 0301 basic medicine, medicine.medical_specialty, Pediatrics, Adult-onset Still's disease, lcsh:Diseases of the musculoskeletal system, business.industry, Published Erratum, MEDLINE, Interleukin, Rheumatology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, medicine, lcsh:RC925-935, business
Abstract

Following publication of the original article [1], it was brought to our attention that the AOSD Consensus Group was incorrectly tagged and therefore not searchable. The publishers apologize for this error.

Published
2020

39. Determinants of patient-reported psoriatic arthritis impact of disease: an analysis of the association with gender in 458 patients from 14 countries

Author

Orbai, A, Perin, J, Gorlier, C, Coates, L, Kiltz, U, Leung, Y, Palominos, P, Cañete, J, Scrivo, R, Balanescu, A, Dernis, E, Tälli, S, Ruyssen-Witrand, A, Soubrier, M, Aydin, S, Eder, L, Gaydukova, I, Lubrano, E, Kalyoncu, U, Richette, P, Husni, M, Smolen, J, De Wit, M, and Gossec, L

Subjects
Adult, Male, Arthritis, Psoriatic, Remission Induction, Comorbidity, Health Status Disparities, Middle Aged, Severity of Illness Index, Article, Sex Factors, Treatment Outcome, Cost of Illness, Risk Factors, Antirheumatic Agents, Sickness Impact Profile, Prevalence, Humans, Female, Patient Reported Outcome Measures, Healthcare Disparities, Aged
Abstract

Sex differences may modify symptoms, disease expression, and treatment effects. The objective of this study was to evaluate the link between life impact and sex in psoriatic arthritis (PsA).Remission and Flare in Psoriatic Arthritis (ReFlaP; ClinicalTrials.gov identifier: NCT03119805) was a study in 14 countries of consecutive adult patients with definite PsA. Participants underwent comprehensive PsA assessment using the following measures: Disease Activity in Psoriatic Arthritis (DAPSA), Minimal Disease Activity (MDA), and Psoriatic Arthritis Impact of Disease (PsAID). Disease activity was compared by sex using t-tests or Wilcoxon tests. The association of PsAID with sex was analyzed using hierarchical generalized linear models.Of 458 participants, 50.2% were male and the mean ± SD age was 53.1 ± 12.6 years. The mean ± SD PsA duration was 11 ± 8.2 years, and 51.5% of participants were being treated with biologic disease-modifying antirheumatic drugs. Women, compared to men, had worse mean ± SD Leeds Enthesitis Index scores (0.8 ± 1.7 versus 0.3 ± 0.9), pain on a numerical rating scale (NRS; range 0-10) (4.7 ± 2.7 versus 3.5 ± 2.7), HAQ DI scores (0.9 ± 0.7 versus 0.5 ± 0.6), fatigue on an NRS (5.2 ± 3 versus 3.3 ± 2.8), and PsAID scores (4.1 ± 2.4 versus 2.8 ± 2.3) (P0.001 for all). Women were also less frequently at treatment target compared to men according to DAPSA (cutoffs of ≤4 for remission and4 and ≤14 for low disease activity; mean ± SD score 16.9 ± 14.9 in women versus 12.6 ± 16.6 in men) and MDA (25.7% versus 50.0%; P0.001 for all) scores. High life impact (PsAID score ≥4) was associated with female sex (odds ratio [OR] 2.3), enthesitis (OR 1.34), tender joints (OR 1.10)(P0.001 for all), and comorbidities (OR 1.22, P = 0.002).High life impact was independently associated with female sex, enthesitis, comorbidities, and tender joints. At treatment target, women had higher life impact compared to men. It is necessary for life impact to become a part of PsA treat-to-target strategies.

Published
2019

41. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis

Author

Galli, M, Antinori, S, Atzeni, F, Meroni, L, Riva, A, Scire, C, Adorni, F, Quartuccio, L, Sebastiani, M, Airo, P, Bazzichi, L, Cristini, F, Del Bono, V, Manfredi, A, Viapiana, O, De Rosa, F, Favalli, E, Petrelli, E, Salvarani, C, Govoni, M, Corcione, S, Scrivo, R, Sarmati, L, Lazzarin, A, Grassi, W, Mastroianni, C, Gaeta, G, Ferraccioli, G, Cutolo, M, De Vita, S, Lapadula, G, Matucci-Cerinic, M, Armignacco, O, Sarzi-Puttini, P, Galli M., Antinori S., Atzeni F., Meroni L., Riva A., Scire C. A., Adorni F., Quartuccio L., Sebastiani M., Airo P., Bazzichi L., Cristini F., Del Bono V., Manfredi A., Viapiana O., De Rosa F., Favalli E., Petrelli E., Salvarani C., Govoni M., Corcione S., Scrivo R., Sarmati L., Lazzarin A., Grassi W., Mastroianni C., Gaeta G. B., Ferraccioli G., Cutolo M., De Vita S., Lapadula G., Matucci-Cerinic M., Armignacco O., Sarzi-Puttini P., Galli, M, Antinori, S, Atzeni, F, Meroni, L, Riva, A, Scire, C, Adorni, F, Quartuccio, L, Sebastiani, M, Airo, P, Bazzichi, L, Cristini, F, Del Bono, V, Manfredi, A, Viapiana, O, De Rosa, F, Favalli, E, Petrelli, E, Salvarani, C, Govoni, M, Corcione, S, Scrivo, R, Sarmati, L, Lazzarin, A, Grassi, W, Mastroianni, C, Gaeta, G, Ferraccioli, G, Cutolo, M, De Vita, S, Lapadula, G, Matucci-Cerinic, M, Armignacco, O, Sarzi-Puttini, P, Galli M., Antinori S., Atzeni F., Meroni L., Riva A., Scire C. A., Adorni F., Quartuccio L., Sebastiani M., Airo P., Bazzichi L., Cristini F., Del Bono V., Manfredi A., Viapiana O., De Rosa F., Favalli E., Petrelli E., Salvarani C., Govoni M., Corcione S., Scrivo R., Sarmati L., Lazzarin A., Grassi W., Mastroianni C., Gaeta G. B., Ferraccioli G., Cutolo M., De Vita S., Lapadula G., Matucci-Cerinic M., Armignacco O., and Sarzi-Puttini P.

Abstract

Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the five most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

Published
2017

42. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis

Author

Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scirè, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airò, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-Puttini P, Galli M., Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scirè, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airò, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-Puttini P, and Galli M.

Abstract

Objectives Hepatitis B (HBV) infection, which is prevalent worldwide, is also frequently seen in patients with rheumatoid arthritis (RA). The Italian Society of Rheumatology (SIR) and the Italian Society of Infectious and Tropical Diseases (SIMIT) endorsed a national consensus process to review the available evidence on HBV management in RA patients and to produce practical, hospital-wide recommendations. Methods The consensus panel consisted of infectious disease consultants, rheumatologists and epidemiologists and used the criteria of the Oxford Center for Evidence-based Medicine to assess the quality of the evidence and the strength of their recommendations. Results A core-set of statements has been developed to help clinicians in the management of patients with RA and HBV infection. Vaccination and prophylaxis of RA patients treated with biological drugs have been also discussed. Conclusions HBV infection is not rare in clinical practice; a screening for HBV in all patients with early arthritis is not universally accepted, while it is considered mandatory before starting any immunosuppressive or hepatotoxic treatment. In fact, a specific risk, associated with the use of biologic treatments, exists for patients with HBV infection, although longitudinal studies of viral reactivation are generally reassuring. RA patients with HBV infection should be referred to the hepatologist and correctly classified into active or inactive carriers. Patients with active hepatitis B should undergo antiviral treatment before starting immunosuppressive treatments. Occult HBV carriers should be monitored or receive prophylaxis on the basis of the risk of reactivation associated with the administered treatment.

Published
2017

43. Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis

Author

Silvia Scriffignano, Perrotta, F. M., Socio, A., Altobelli, A., Sessa, P., Scrivo, R., Valesini, G., and Lubrano, E.

Subjects
psoriatic arthritis, Cross-Sectional Studies, Italy, flare, disease activity, outcomes, Surveys and Questionnaires, Arthritis, Psoriatic, Humans, Reproducibility of Results, Translating, Symptom Flare Up
Abstract

The aim of the present study was to validate an Italian version of the GRAPPA flare instrument to identify patients with psoriatic arthritis (PsA) with a possible disease flare.This was a cross-sectional study enrolling consecutively PsA patients classified with CASPAR criteria. Inclusion criteria were: age ≥18 years and stable treatment (at least six months of follow-up) with conventional synthetic or biological DMARDs. The flare questionnaire was administered at baseline and within a two-week interval. Internal consistency of the questionnaire was evaluated with Cronbach's alpha coefficient. Construct validity of flare questionnaire was assessed using the correlation between flare score and disease activity indices, HAQ and serum C-reactive protein. Cohen's κ was performed to assess the agreement level between the patient's perception of flare and the score of the questionnaire. Finally, test-retest was performed to assess the reliability of the instrument.46 PsA patients were enrolled in this study. Of these, 30.4% reported a status of flare of their disease. The questionnaire was internally consistent (alpha=0.81). Moreover, the questionnaire score correlated with the main disease activity indices (Spearman Rho ranging from 0.30 to 0.66; p0.01). The score of flare questionnaire showed a moderate agreement with the perception of flare from the patients (Cohen's κ=0.54). Test-retest reliability showed a good intra-class correlation.This initial validation of the Italian version of the GRAPPA flare instrument was favourable. Our results confirm the utility of this questionnaire in the assessment of flare in PsA.

Published
2018

44. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis

Author

Galli, M., Antinori, S., Atzeni, F., Meroni, L., Riva, A., Scirè, C. A., Adorni, F., Quartuccio, L., Sebastiani, M., Airò, P., Bazzichi, L., Cristini, F., Del Bono, V., Manfredi, A., Viapiana, O., Rosa, F., Favalli, E., Petrelli, E., Salvarani, C., Govoni, M., Corcione, S., Scrivo, R., Sarmati, L., Lazzarin, A., Grassi, W., Mastroianni, C., Gaeta, G. B., Ferraccioli, G., Cutolo, M., Vita, S., Giovanni Lapadula, Matucci-Cerinic, M., Armignacco, O., Sarzi-Puttini, P., Galli, M, Antinori, S, Atzeni, F, Meroni, L, Riva, A, Scire, C, Adorni, F, Quartuccio, L, Sebastiani, M, Airo, P, Bazzichi, L, Cristini, F, Del Bono, V, Manfredi, A, Viapiana, O, De Rosa, F, Favalli, E, Petrelli, E, Salvarani, C, Govoni, M, Corcione, S, Scrivo, R, Sarmati, L, Lazzarin, A, Grassi, W, Mastroianni, C, Gaeta, G, Ferraccioli, G, Cutolo, M, De Vita, S, Lapadula, G, Matucci-Cerinic, M, Armignacco, O, Sarzi-Puttini, P, Galli, Massimo, Antinori, Spinello, Atzeni, Fabiola, Meroni, Luca, Riva, Agostino, Scirè, Carlo, Adorni, Fulvio, Quartuccio, Luca, Sebastiani, Marco, Airò, Paolo, Bazzichi, Laura, Cristini, Francesco, Del Bono, Valerio, Manfredi, Andreina, Viapiana, Ombretta, De Rosa, Francesco, Favalli, Ennio, Petrelli, Enzo, Salvarani, Carlo, Govoni, Marcello, Corcione, Silvia, Scrivo, Rossana, Sarmati, Loredana, Lazzarin, Adriano, Grassi, Walter, Mastroianni, Claudio, Gaeta, Giovanni Battista, Ferraccioli, Gianfranco, Cutolo, Maurizio, De Vita, Salvatore, Lapadula, Giovanni, Matucci-Cerinic, Marco, Armignacco, Orlando, and Sarzi-Puttini, Piercarlo

Subjects
Fungal infection, rheumatoid arthritis, Lung Diseases, Settore MED/17 - Malattie Infettive, Recommendations, Pneumonia, Rheumatoid arthritis, NO, Arthritis, Rheumatoid, Rheumatoid, Humans, Histoplasmosis, Coccidioidomycosis, Lung Diseases, Fungal, Pneumocystis, Pneumonia, Pneumocystis, fungal infection, Arthritis, Antirheumatic Agents, Cryptococcosis, Pulmonary Aspergillosis, Recommendation, Fungal, recommendations, pneumonia
Abstract

Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the five most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

Published
2017

45. Prise en charge de l'infection par le virus de l'hépatite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne [Italian consensus guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis]

Author

Sebastiani, M., Atzeni, F., Milazzo, L., Quartuccio, L., Scire, C., Gaeta, G. B., Lapadula, G., Armignacco, O., Tavio, M., Olivieri, I., Meroni, P., Bazzichi, L., Grassi, W., Mathieu, A., Mastroianni, C., Sagnelli, E., Santantonio, T., Uberti Foppa, C., Puoti, M., Sarmati, L., Airo, P., Epis, O. M., Scrivo, R., Gargiulo, M., Riva, A., Manfredi, A., Ciancio, G., Zehender, G., Taliani, G., Meroni, L., Sollima, S., Sarzi-Puttini, P., and Galli, M.

Published
2018

46. Porphyromonas gingivalis in the tongue biofilm is associated with clinical outcome in rheumatoid arthritis patients

Author

Ceccarelli, F, primary, Orrù, G, additional, Pilloni, A, additional, Bartosiewicz, I, additional, Perricone, C, additional, Martino, E, additional, Lucchetti, R, additional, Fais, S, additional, Vomero, M, additional, Olivieri, M, additional, di Franco, M, additional, Priori, R, additional, Riccieri, V, additional, Scrivo, R, additional, Shoenfeld, Y, additional, Alessandri, C, additional, Conti, F, additional, Polimeni, A, additional, and Valesini, G, additional

Published
2018
Full Text
View/download PDF

47. SAT0318 Do patients in remission in psoriatic arthritis, have less fatigue? and does this depend on the definition of remission? an analysis of 304 patients

Author

Gorlier, C., primary, Puyraimond-Zemmour, D., additional, Kiltz, U., additional, Orbai, A.-M., additional, Leung, Y.Y., additional, Palominos, P., additional, Cañete, J.D., additional, Scrivo, R., additional, Balanescu, A., additional, Dernis, E., additional, Talli, S., additional, Ruyssen-Witrand, A., additional, Soubrier, M., additional, Aydin, S., additional, Eder, L., additional, Gaydukova, I., additional, Lubrano, E., additional, Coates, L., additional, Kalyoncu, U., additional, Smolen, J., additional, De Wit, M., additional, and Gossec, L., additional

Published
2018
Full Text
View/download PDF

49. THU0334 Evaluation of subclinical vascular damage in patients with polymyalgia rheumatica: a cross-sectional study using an integrated, non-invasive approach of color doppler ultrasound and cardio-ankle vascular index (CAVI) measurement of arterial stiffness

Author

Sessa, P, primary, Rutigliano, IM, additional, Scrivo, R, additional, Silvestri, V, additional, Ciciarello, F, additional, Torre, G La, additional, Conti, F, additional, Priori, R, additional, Alessandri, C, additional, Riccieri, V, additional, Franco, M Di, additional, Gossetti, B, additional, and Valesini, G, additional

Published
2017
Full Text
View/download PDF

50. FRI0028 In vitro inhibitory effect of etanercept on autophagy: a new mechanism of action of tnf inhibitors in rheumatoid arthritis

Author

Vomero, M, primary, Capozzi, A, additional, Barbati, C, additional, Colasanti, T, additional, Manganelli, V, additional, Ceccarelli, F, additional, Spinelli, FR, additional, Conti, F, additional, Perricone, C, additional, Finucci, A, additional, Pendolino, M, additional, Scrivo, R, additional, Misasi, R, additional, Sorice, M, additional, Valesini, G, additional, and Alessandri, C, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results